During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Citi Research raises price target for Eli Lilly, citing improved risk-adjusted sales outlook for GLP-1 agonist orforglipron. With Phase 3 trials ongoing since 2023, concerns about liver toxicity diminish. Analysts foresee potential sales surpassing $85 billion, closely watching competitive landscape.
Microvast said fourth-quarter revenue increased 61.4% year-over-year to $104.58 million, which beat the consensus estimate of $94.43 million, according to Benzinga Pro. The company reported an adjusted loss of 4 cents per share, which beat estimates for a loss of 7 cents per share.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.